A
B
C
D
E
F
G
H
I
K
L
M
N
O
P
Q
R
S
T
U
V
W

Lonza

Company-logo  COMPANY DETAILS
Lonza
Muenchensteinerstrasse 38
Basel
4002
Switzerland

Website
Mail
Call
  +41 61 316 8111


Printer
  +41 61 316 9111

ACTIVE CATEGORIES

nutraceutical and functional food ingredients, vitamins


Facebook   
Linkedin   
Twitter   
Youtube   

Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment. 

Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. 

Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources. 

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com.

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.



Articles On NutritionInsight
FormattedPicture

NUTRITION & HEALTH NEWS

Nutrition business driving Lonza’s first-quarter “solid” performance but Speciality Ingredients segment faces challenges

18 Apr 2019 --- Swiss multinational Lonza is continuing its positive momentum in its newly aligned segment, Lonza Pharma Biotech & Nutrition (LPBN), according to a first-quarter overview.... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

Key suppliers respond to French agency’s warning against joint supplements use

10 Apr 2019 --- Suppliers of joint health solutions have questioned a recent assessment by French authorities which claims that supplements containing glucosamine or chondroitin sulfate may cause... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

Patent-pending probiotic mix dissolves harmful biofilms, may curb development of Crohn’s disease

04 Apr 2019 --- A patent-pending probiotic mix may help shield patients who suffer from gastrointestinal (GI) diseases from harmful biofilms – antibiotic-resistant microbial communities. This... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

Mobility and health span pivotal consumer demands in collagen supplementation

04 Apr 2019 --- As life expectancy has increased globally, consumer attention is shifting towards improving the quality of senior life, in terms of mobility and maintaining activity levels. As... Read More

FormattedPicture

BUSINESS NEWS

Bugs as drugs: Chr. Hansen and Lonza enter live biotherapeutic products joint venture

03 Apr 2019 --- Chr. Hansen’s establishment of a 50/50 joint venture together with Lonza in the live biotherapeutic products (LBPs) industry is the next phase in the evolution of how healthy... Read More




Video Interviews
FormattedPicture

Addressing clean label supplement demands

11 Feb 2019 --- Lonza recently revealed the global launch of its latest dosage form innovation: Capsugel Vcaps Plus plant-based capsules. The first of the next-generation clean label solutions to be marketed worldwide is the Vcaps Plus Purple Carrot capsule, following the successful introduction of the Vcaps Plus Blue Spirulina capsule in Europe earlier this year. The high-performance capsule shell is made using plant-based hypromellose (HPMC) and water only, without any preservatives. A colorant derived from purple carrots is used to match the desired shade as closely as possible, while maintaining a natural appearance in the finished supplement. Achieving unique visual appeal, the purple carrot color also provides masking capabilities.

FormattedPicture

Innovating in ready-to-market formulations

17 Jan 2019 --- Stephane Vouche, of Lonza Capsugel, spoke to NutritionInsight at Health Ingredients Europe (HiE) in 2018 on innovating in ready-to-market formulations. Vouche shared that Lonza was presenting new formulations at the show. One particular innovation included a combination capsule with Lonza's UCT-II ingredient for joint health with curcumin. This combination creates a powerful one-pill solution, meaning consumers do not need to take multiple pills, Vouche said.

FormattedPicture

Integrating Capsugel innovation

22 May 2018 --- Lonza Consumer Health & Nutrition brought innovation through form and function for its latest ingredients, delivery systems and finished product formulations for the nutraceuticals industry to Vitafoods Europe 2018. Visitors could see how innovative ingredients can be combined with cutting-edge dosage forms from the legacy Capsugel business, including DUOCAP capsule-in-capsules and Lipid Multi Particulate (LMP) technology, to create market-ready products positioned on a healthy aging, probiotics or active & sports nutrition platform, among others. In addition, the company highlighted its blue algae Vcaps Plus Spirulina capsule, the next generation of vegetarian food colored capsules, designed to support the development of true clean label solutions.

FormattedPicture

The Growing Science Behind Memree for Cognitive Health

10 Mar 2015 --- Lonza has presented new research results on its Memree line of products. A new study confirms published in Lipids in health and disease confirmed that supplementation with MemreePlus can decrease the stress response in chronically stressed male adults.




Nutrition Focus
FormattedPicture
18 Mar 2019 | Lonza

Moving with the times: A new generation joint health solution for today’s consumer

The aging consumer has growing expectations of bone and joint health solutions, thanks to the mainstreaming of sports nutrition and a growing focus on active aging. According to Innova... Read More

FormattedPicture
02 Oct 2018 | Lonza

Bone and joint health: Increased focus on mobility and healthy aging

Products featuring bone & joint health claims are on the rise, with Innova Market Insights data showing a compound annual growth rate of 13 percent between 2013 and... Read More




A
B
C
D
E
F
G
H
I
K
L
M
N
O
P
Q
R
S
T
U
V
W